Use of 5-Aminosalicylic Acid for Treatment of Ulcerative Colitis in Different Dosage Modes

Шапина, М. В.; Халиф, И. Л.

doi:10.21518/2079-701x-2017-15-44-50

Cited by 10 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Оказалось, что в группе однократного приема и в группе трехкратного приема суточной дозы месалазина сопоставимое (79,1% и 75,7%) число пациентов перешло в клиническую ремиссию. На основании чего исследователи рекомендуют отдавать предпочтение однократному приему суточной дозы перорального месалазина, так как это положительно сказывается на уровне приверженности и в конечном счете увеличивает эффективность всего лечения [33].…”

Section: основная частьunclassified

Adherence to treatment in patients with inflammatory bowel disease

et al. 2021

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a common pathology that reduces the quality and duration of a patient’s life. The cornerstone of treatment of IBD patients is polypharmacotherapy based on the use of salicylates, antibiotics, immunomodulatory and biological drugs, and topical dosage forms. Multicomponent treatment has shown to reduce the quality of life and negatively affect adherence to drug therapy in IBD patients.One of the leading causes of treatment failure is low treatment adherence, which leads to disease progression, disability, and increased financial costs. Currently, there are many factors that affect adherence to therapy, some of them are modifiable, which creates opportunities to improve the effectiveness of existing medical interventions. However, the available data on the level of adherence in IBD patients are not numerous and homogeneous, so a low level of adherence to drug therapy in IBD patients is registered in 7–72% of cases.An important issue in understanding adherence in IBD patients is a lack of research on the level of adherence to counselling and lifestyle modification. However, the course of IBD, treatment features related to the duration of therapy and necessary lifestyle modifications (nutrition), as well as regular monitoring of laboratory and instrumental parameters determine the need to assess adherence to lifestyle modification and counselling along with adherence to drug therapy.

show abstract

Section: основная частьunclassified

Adherence to treatment in patients with inflammatory bowel disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Currently, mesalazine (MS) -5-aminosalicylic acid -is the main component of drugs used in the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Numerous studies have proven the effectiveness of MS oral administration in both induction and maintenance of remission in patients with mild to moderate activity colitis [1][2][3][4]. According to the scientists [5][6][7][8], mesalazine exhibits a local anti-inflammatory effect, so the concentration of the drug in contact with the damaged intestinal wall mucosa and the duration of this contact are extremely important.…”

Section: Introductionmentioning

confidence: 99%

Complex compounds of mesalazine with cyclodextrins and the prospect of their application in the ulcer disease treatment

Borisova,

Gimadieva,

Zimin

et al. 2023

BIO Web Conf.

View full text Add to dashboard Cite

Mesalazine is highly effective in the treatment of ulcerative colitis and Crohn’s disease. However, in view of the fact that this compound is easily absorbed in the upper small intestine and cannot reach the large intestine at a therapeutic concentration, it is relevant to enclose it in the cavity of cyclodextrins through the formation of inclusion complexes of the “guest–host” type. Mesalazine complexation with α-, β-, γ- cyclodextrins was studied by spectrophotometric method in aqueous solutions. We established that the composition of the resulting complexes is 1:1. In the temperature range 296 - 321 K, the stability constants are calculated, and the thermodynamic parameters of complex formation are determined. We developed a technique for the synthesis of complexes, and a prototype, and studied its antiulcer activity. The authors established that the complex of mesalazine with β- cyclodextrin has a more pronounced antiulcer activity compared to the original substances, and approximately the same action as the reference drug (Omez). However, the amount of mesalazine in the complex was only 12% wt., the remaining 88% wt. account for β- cyclodextrin. The results obtained indicate the possibility of complex formation between mesalazine and α-, β-, γ- cyclodextrins. The resulting complex compounds can become the basis of new anti-inflammatory and antiulcer drugs.

show abstract

Hygienic Rationing of Mesalazine as Salicylic Acid Derivative

Gorokhova

Martynova²,

Mikhailova

2018

HAS

View full text Add to dashboard Cite

Introduction. Hygienic rationing of the content of adverse substances in the air on the basis of an experimental study of their toxicity is aimed at the elaboration and creation of safe working conditions. Material and methods. The toxic properties of the salicylic acid derivative (Mesalazine) have been studied in the experiments on out-bred and linear mice, rats, Guinea pigs, and rabbits kept in standard vivarium conditions and quarantined. In the experiments, various modes (single, repeated, chronic) and ways of exposure (intragastric, inhalation, epicutaneous) were simulated. The average lethal dose (LD50) of Mesalazine and the threshold of a single acute exposure (Limas) were determined; irritant effect on the skin and mucous membranes, cumulative and allergenic activity were estimated. In subacute and chronic intake, the main target organs were determined based on the results of biochemical and hematological studies. Results. By the value of the average lethal doses Mesalazine has been established to have to be classified as a substance of the 3rd hazard class (moderately hazardous). There were no significant differences in the species and the gender susceptibility of the animals to Mesalazine: the coefficient of species differences was 2.84; the coefficient of the gender susceptibility was 1.2, which was less than 3 units. In terms of the degree of specific blood damage, Mesalazine belongs to class V (no effect of the selective influence of the drug on the imbalance of various hemoglobin forms). Mesalazine has a weak ability to cumulate, have no irritating effects on the eyes and skin. Skin-resorptive and sensitizing effects were not revealed. Limas under the conditions of dynamic inhalation exposure is set at 30.4 mg/m3. Conclusion. Maximum allowable concentration (MAC) of Mesalazine in the air of the working area as 0.5 mg/m3 is recommended (hazard class II). Compliance with this standard will ensure the health preservation and will eliminate the risk of developing occupational diseases.

show abstract

Use of 5-Aminosalicylic Acid for Treatment of Ulcerative Colitis in Different Dosage Modes

Cited by 10 publications

References 33 publications

Adherence to treatment in patients with inflammatory bowel disease

Adherence to treatment in patients with inflammatory bowel disease

Complex compounds of mesalazine with cyclodextrins and the prospect of their application in the ulcer disease treatment

Hygienic Rationing of Mesalazine as Salicylic Acid Derivative

Contact Info

Product

Resources

About